Literature DB >> 32415526

Cannabidiol Prevents the Expression of the Locomotor Sensitization and the Metabolic Changes in the Nucleus Accumbens and Prefrontal Cortex Elicited by the Combined Administration of Cocaine and Caffeine in Rats.

José Pedro Prieto1, Ximena López Hill1, Jessika Urbanavicius1, Verónica Sanchez2, Xavier Nadal2,3, Cecilia Scorza4.   

Abstract

In the last years, clinical and preclinical researchers have increased their interest in non-psychotomimetic cannabinoids, like cannabidiol (CBD), as a strategy for treating psychostimulant use disorders. However, there are discrepancies in the pharmacological effects and brain targets of CBD. We evaluated if CBD was able to prevent the locomotor sensitization elicited by cocaine and caffeine co-administration. The effect of CBD on putative alterations in the metabolic activity of the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), and its respective subregions (cingulated, prelimbic, and infralimbic cortices, and NAc core and shell) associated to the behavioral response, was also investigated. Rats were intraperitoneally and repeatedly treated with CBD (20 mg/kg) or its vehicle, followed by the combination of cocaine and caffeine (Coc+Caf; 5 mg/kg and 2.5 mg/kg, respectively) or saline for 3 days. After 5 days of withdrawal, all animals were challenged with Coc+Caf (day 9). Locomotor activity was automatically recorded and analyzed by a video-tracking software. The metabolic activity was determined by measuring cytochrome oxidase-I (CO-I) staining. Locomotion was significantly and similarly increased both in Veh-Coc+Caf- and CBD-Coc+Caf-treated animals during the pretreatment period (3 days); however, on day 9, the expression of the sensitization was blunted in CBD-treated animals. A hypoactive metabolic response and a hyperactive metabolic response in mPFC and NAc subregions respectively were observed after the behavioral sensitization. CBD prevented almost all these changes. Our findings substantially contribute to the understanding of the functional changes associated with cocaine- and caffeine-induced sensitization and the effect of CBD on this process.

Entities:  

Keywords:  Behavior; CBD; Cytochrome oxidase-I; Metabolic activity; Motivational circuit; Psychostimulants

Mesh:

Substances:

Year:  2020        PMID: 32415526     DOI: 10.1007/s12640-020-00218-9

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  47 in total

1.  Repeated cocaine alters glutamate receptor subunit levels in the nucleus accumbens and ventral tegmental area of rats that develop behavioral sensitization.

Authors:  L Churchill; C J Swanson; M Urbina; P W Kalivas
Journal:  J Neurochem       Date:  1999-06       Impact factor: 5.372

Review 2.  The cutting of cocaine and heroin: A critical review.

Authors:  Julian Broséus; Natacha Gentile; Pierre Esseiva
Journal:  Forensic Sci Int       Date:  2016-02-26       Impact factor: 2.395

Review 3.  Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens.

Authors:  J L Cornish; P W Kalivas
Journal:  J Addict Dis       Date:  2001

4.  Enhanced neuronal and blunted hemodynamic reactivity to cocaine in the prefrontal cortex following extended cocaine access: optical imaging study in anesthetized rats.

Authors:  Craig P Allen; Kicheon Park; Ang Li; Nora D Volkow; George F Koob; Yingtian Pan; Xiu-Ti Hu; Congwu Du
Journal:  Addict Biol       Date:  2018-03-05       Impact factor: 4.280

5.  Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression.

Authors:  Erica J Carrier; John A Auchampach; Cecilia J Hillard
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-03       Impact factor: 11.205

6.  Rescuing cocaine-induced prefrontal cortex hypoactivity prevents compulsive cocaine seeking.

Authors:  Billy T Chen; Hau-Jie Yau; Christina Hatch; Ikue Kusumoto-Yoshida; Saemi L Cho; F Woodward Hopf; Antonello Bonci
Journal:  Nature       Date:  2013-04-03       Impact factor: 49.962

Review 7.  Glial and neuroinflammatory targets for treating substance use disorders.

Authors:  Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2017-08-31       Impact factor: 4.492

Review 8.  Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.

Authors:  Paul W Czoty; William W Stoops; Craig R Rush
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

9.  Identification and Quantification of Cocaine and Active Adulterants in Coca-Paste Seized Samples: Useful Scientific Support to Health Care.

Authors:  Juan Andrés Abin-Carriquiry; Marcela Martínez-Busi; Martín Galvalisi; Manuel Minteguiaga; José Pedro Prieto; María Cecilia Scorza
Journal:  Neurotox Res       Date:  2018-03-13       Impact factor: 3.911

Review 10.  The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder.

Authors:  Yann Chye; Erynn Christensen; Nadia Solowij; Murat Yücel
Journal:  Front Psychiatry       Date:  2019-02-19       Impact factor: 4.157

View more
  3 in total

Review 1.  Cannabidiol and substance use disorder: Dream or reality.

Authors:  Saeideh Karimi-Haghighi; Yasaman Razavi; Daniela Iezzi; Andrew F Scheyer; Olivier Manzoni; Abbas Haghparast
Journal:  Neuropharmacology       Date:  2022-01-13       Impact factor: 5.273

2.  A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors.

Authors:  Carolina Echeverry; Giselle Prunell; Camila Narbondo; Verónica Sánchez de Medina; Xavier Nadal; Miguel Reyes-Parada; Cecilia Scorza
Journal:  Neurotox Res       Date:  2020-09-04       Impact factor: 3.911

Review 3.  Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.

Authors:  Francisco Navarrete; María Salud García-Gutiérrez; Ani Gasparyan; Amaya Austrich-Olivares; Jorge Manzanares
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.